Compare Alcon AG (ALC) vs Oracle Corporation (ORCL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Oracle Corporation — how do they compare? Alcon AG trades at $66.89 (market cap $32.69B), while Oracle Corporation trades at $138.91 (market cap $407.87B). The key difference: Oracle Corporation is far larger — about 12.5× Alcon AG's market cap, and Oracle Corporation pays the higher dividend (1.41%). Which is the better fit depends on your goals.
| ALC | ORCL | |
|---|---|---|
Market Cap | $32.69B | $407.87B |
Sector | Health | Technology |
52-Week High | $92.22 | $328.33 |
52-Week Low | $62.02 | $136.39 |
Enterprise Value | $36.28B | $537.12B |
Dividend Yield | 0.54% | 1.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Oracle (ORCL) trades at $143.76, up 2.49% today, with a bullish technical oscillator signal but bearish moving average trend. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.11 exceeding the $1.96 estimate. Revenue grew to $57.40 billion in 2025, and net income margin improved to 25.37%. Recent news highlights Oracle's AI infrastructure growth and partnership with OpenAI, driving investor optimism.
The outlook for Oracle is positive, supported by AI-driven demand and consistent earnings outperformance. Key risks include high debt levels and competitive pressures in cloud services. Analyst consensus is bullish with a $259 price target, suggesting significant upside from current levels, but investors should monitor execution on AI investments and macroeconomic conditions affecting tech spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →
